drugset / Trial / NCT00568074

Efficacy and Safety of Repaglinide, Glurenorm® and Glucobay® in Chinese Subjects With Type 2 Diabetes

NCT00568074

Phase 4 Completed 131 enrolled Novo Nordisk A/S
RandomizedParallel-groupOpen-labelTreatment

Summary

This trial is conducted in Asia. The aim of this trial is to compare the efficacy and safety of repaglinide and Glurenorm® and Glucobay® given as the mono-therapy in Chinese subjects being treatment-naive type 2 diabetics.

Timeline

Start
2003-12-16
Primary completion
2004-09-02
Completion
2004-09-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Acarbose Unknown
Subject GLIQUIDONE Small molecule
Subject Repaglinide Small molecule